Intraday Price Movement and Trading Activity
On 10 Feb 2026, Venus Remedies Ltd (Stock ID: 568580) demonstrated a remarkable turnaround after enduring seven consecutive days of decline. The stock opened at ₹707.00 and steadily climbed to touch its upper circuit price band of ₹745.20, marking a ₹35.45 increase or a 4.99% gain on the day. This outperformance was notable against the Pharmaceuticals & Biotechnology sector’s modest 0.42% rise and the Sensex’s 0.36% gain, underscoring the stock’s relative strength.
Despite the strong price appreciation, the total traded volume was relatively modest at 0.15414 lakh shares, translating to a turnover of ₹1.13 crore. The weighted average price indicated that a significant portion of the volume traded closer to the day’s low price, suggesting that while the stock surged, some investors were cautious in their buying levels.
Technical Indicators and Market Sentiment
From a technical standpoint, Venus Remedies Ltd’s last traded price (LTP) of ₹745.20 remains above its 100-day and 200-day moving averages, signalling a long-term bullish trend. However, it still trades below its short-term moving averages of 5-day, 20-day, and 50-day, indicating some resistance in the near term. This mixed technical picture suggests that while the stock has regained momentum, it may face hurdles before establishing a sustained uptrend.
Investor participation, as measured by delivery volume, has declined sharply. On 9 Feb 2026, delivery volume stood at 2,040 shares, down 46.58% compared to the five-day average. This drop in delivery volume implies that a larger proportion of trades may be speculative or intraday in nature, rather than long-term accumulation.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Upper Circuit Trigger and Regulatory Freeze
The stock’s surge to the upper circuit limit triggered an automatic regulatory freeze on further trading in Venus Remedies Ltd shares for the remainder of the day. This mechanism is designed to curb excessive volatility and protect investors from abrupt price swings. The 5% price band limit was reached precisely, with the stock closing at ₹745.20, the maximum permissible price for the session.
Such upper circuit hits often reflect a strong imbalance between demand and supply, with buy orders overwhelming sell orders. In this instance, the unfilled demand indicates that many buyers were unable to acquire shares at the closing price, potentially setting the stage for continued interest in subsequent sessions.
Market Capitalisation and Sector Context
Venus Remedies Ltd is classified as a micro-cap company with a market capitalisation of approximately ₹995 crore. Operating within the Pharmaceuticals & Biotechnology sector, the company’s recent price action stands out amid a sector that has seen only modest gains. The stock’s mojo score of 77.0 and a mojo grade of Buy (downgraded from Strong Buy on 1 Feb 2026) reflect a positive but cautious outlook from market analysts.
The downgrade in mojo grade suggests that while the stock remains attractive, some headwinds or valuation concerns may temper expectations. Nonetheless, the current price momentum and upper circuit hit highlight renewed investor interest and potential for further upside.
Liquidity and Trading Considerations
Liquidity remains adequate for Venus Remedies Ltd, with the stock’s traded value representing about 2% of its five-day average traded value. This level of liquidity supports trade sizes up to ₹0.05 crore without significant market impact, making it accessible for retail and institutional investors alike.
However, the falling delivery volumes caution that the recent rally may be driven more by short-term speculative demand rather than sustained accumulation by long-term investors. Market participants should monitor upcoming sessions for confirmation of trend continuation or potential profit-taking.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Outlook and Investor Takeaways
Venus Remedies Ltd’s upper circuit hit on 10 Feb 2026 signals a significant shift in market sentiment after a prolonged period of decline. The strong buying pressure and price appreciation outpaced sector and benchmark indices, suggesting renewed confidence in the company’s prospects.
Investors should weigh the positive technical signals against the reduced delivery volumes and the recent downgrade in mojo grade. While the stock’s micro-cap status and ₹995 crore market cap offer growth potential, they also entail higher volatility and risk.
Given the unfilled demand and regulatory freeze, the stock may experience continued interest in the near term. However, prudent investors are advised to monitor volume trends, price action relative to moving averages, and sector developments before committing fresh capital.
Overall, Venus Remedies Ltd remains a compelling candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s micro-cap segment, provided they maintain a disciplined approach to risk management.
Summary of Key Metrics:
- Closing Price: ₹745.20 (Upper Circuit)
- Daily Gain: 4.99%
- Market Capitalisation: ₹995 crore (Micro Cap)
- Mojo Score: 77.0 (Buy, downgraded from Strong Buy on 1 Feb 2026)
- Volume Traded: 0.15414 lakh shares
- Turnover: ₹1.13 crore
- Delivery Volume (9 Feb): 2,040 shares (-46.58% vs 5-day avg)
- Sector 1D Return: 0.42%
- Sensex 1D Return: 0.36%
As Venus Remedies Ltd navigates this phase of heightened market interest, investors should remain vigilant to evolving price dynamics and sector fundamentals to capitalise on potential opportunities while managing downside risks.
Unlock special upgrade rates for a limited period. Start Saving Now →
